阿昔洛韦联合小儿肺热咳喘口服液对婴幼儿呼吸道合胞病毒肺炎的疗效分析

目的 研究阿昔洛韦联合小儿肺热咳喘口服液对婴幼儿呼吸道合胞病毒肺炎的疗效.方法 选择2012年10月～ 2015年9月在我院进行诊治的呼吸道合胞病毒肺炎患儿90例,将其随机分为观察组与对照组,每组各45例.观察组采用阿昔洛韦联合小儿肺热咳喘口服液治疗,对照组采用阿昔洛韦治疗,比较两组治疗效果.结果 观察组总有效率为93.33％,明显高于对照组84.44％(P＜0.05);两组患儿的住院时间、咳嗽减轻时间、体温复常时间、哕音消失时间分别进行统计学比较,均有显著性差异(P＜0.05);治疗前两组患儿CD3+、CD4+、CD8+和IL-2水平比较,差异无统计学意义(P＞0.05),同组治疗后CD4+、CD8+和IL-2水平与治疗前相比,差异有统计学意义(P＞0.05),两组治疗后CD3+、CD4+、CD8+和IL-2水平无明显差异(P＞0.05);两组不良反应发生率比较差异无统计学意义(P＞0.05).结论 阿昔洛韦联合小儿肺热咳喘口服液治疗小儿呼吸道合胞病毒肺炎具有显著的临床效果,值得推广应用.

The curative effect of acyclovir combined with infantile feirekechuan oral liquid in the treatment of infants with respiratory syncytial virus pneumonia

Objective To analyze the curative effect of acyclovir combined with infantile feirekechuan oral liquid in the treatment of infants with respiratory syncytial virus pneumonia.Methods From October 2012 to September 2015,90 children with respiratory syncytial virus pneumonia were selected as research subjects in our hospital and they were divided into two groups randomly.The observation group was treated with acyclovir combined with infantile feirekechuan oral liquid and the control group was treated with acyclovir.The clinical effect was compared between two groups.Results The total effective rate in the observation group was 93.33％,which was significantly higher than that (84.44％) of the control group (P ＜0.05).There were statistically significant differences of the hospitalized time,cough reduce time,temperature recovery time and rale disappearing time between the two groups (P ＜ 0.05).There was no significant difference in the levels of CD3 +,CD4 + and CD8 + between the two groups before treatment (P ＞ 0.05)and there was significant difference in the levels of CD4 +,CD8 +,IL-2 in the same group before and after treatment,but there was no significant difference between two groups after treatment (P ＞ 0.05).In addition,there was no significant difference in the incidence of adverse reactions between the two groups (P ＞0.05).Conclusions The curative effect of acyclovir combined with infantile feirekechuan oral liquid for respiratory syncytial virus pneumonia was significant,which is worthy of promotion.